Cytomed Therapeutics (GDTC)Choo Chee Kong disclosed a 24.9% stake in GDTC and may seek to influence the company 24.9%
Choo Chee Kong disclosed a 24.9% stake in GDTC and may seek to influence the company.
- 24.9%
- Stake
- 2.97M
- Shares owned
- Stake as of
- Oct 6, 2026
- Filed
- Oct 13, 2026
Context
Written by software from the filings listed below · Oct 13, 2026
- What was filed. Choo Chee Kong filed a SCHEDULE 13D/A on Oct 13, 2026 reporting 2,974,746 shares, 24.92% of the class of Cytomed Therapeutics (GDTC). SEC Schedule 13D
One more point, with the facts they come from, are in OQRO Pro.
Unlock OQRO ProThe story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
How to read SEC Schedule 13D
A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.
Full guide: Schedule 13D vs Schedule 13G: what is the difference?
What else is on file for Cytomed Therapeutics
For Cytomed Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GDTC page.
How this filing works
Other disclosures at Cytomed Therapeutics
Everything OQRO holds on this company is on its GDTC page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data